• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

AstraZeneca's flagship Tagrisso helps lung cancer patients live longer in pivotal study

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 09, 2019 at 10:42: AM
via AstraZeneca is off to a good start in August. After its PARP inhibitor Lynparza scored in a prostate cancer trial earlier this week, the British drugmaker on Friday disclosed that its star cancer drug Tagrisso helped patients with a certain type of lung cancer live longer in a late-stage study.

article source
 




Top Bottom
Back
Quote